SecBot SecBot
8-K ·Filed Apr 30, 2026

LH

LABCORP HOLDINGS INC.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0000920148-26-000135
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised guidance and strong Q1 beat (especially on GAAP EPS) should drive positive momentum. Watch for continued organic growth in Diagnostics (3.1% organic) and Central Labs (11.3% growth). The $8.64B backlog (+5.6% YoY) provides visibility into Biopharma revenue. Monitor upcoming acquisitions and the new Central Lab facility investment.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$256.10
T+0 close · Apr 30, 2026 · via day close
Latest settled
+17.60%
T+60 · $301.17
Vs SPY
+14.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 30 $256.10entry
  2. T+1 · 7mo ago −0.37%α −0.59% · $255.14
  3. T+5 · 6mo ago +0.49%α −1.24% · $257.34
  4. T+20 · 6mo ago +1.55%α −3.68% · $260.06
  5. T+60 · 4mo ago +17.60%α +14.49% · $301.17

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Labcorp reported Q1 2026 revenue of $3.54B (+5.8% YoY) and diluted GAAP EPS of $3.35 (+32.8% YoY), beating consensus estimates. The company raised its full-year 2026 Adjusted EPS guidance to $17.70-$18.35 (up $0.13 at the midpoint) and enterprise revenue growth guidance to 5.0%-6.1%. Strong operational performance across both Diagnostics and Biopharma segments, coupled with raised guidance, signals accelerating momentum.

Key Financial Metrics

EPS
$3.35
est $4.09 · -18.1%
Revenue
$3.5B
est $3.5B · +0.8% · +5.8% YoY
Rating
beat
Guidance
$14.65B-$14.80B
raised
Free Cash Flow
$70.5M
Gross Margin
28.7%

Key Facts

  • Q1 2026 revenue of $3.54B, up 5.8% YoY from $3.35B
  • Diluted GAAP EPS of $3.35, up 32.8% YoY from $2.52
  • Adjusted EPS of $4.25, up 10.6% YoY from $3.84
  • Raised FY2026 Adjusted EPS guidance to $17.70-$18.35 (prior $17.55-$18.25)
  • Raised FY2026 enterprise revenue growth guidance to 5.0%-6.1% (prior 4.7%-6.0%)
  • Diagnostics segment revenue $2.76B (+5.0% YoY), AOI margin 16.6% (+30bps)
  • Biopharma segment revenue $780.6M (+8.2% YoY), AOI margin 15.5% (+60bps)
  • Free cash flow of $70.5M vs -$107.5M in prior year quarter
  • Backlog of $8.64B, up 5.6% YoY
  • Repurchased $98M of stock and paid $61.2M in dividends in Q1

Financial Impact

Raised FY2026 Adjusted EPS midpoint by $0.13 to $18.03, revenue midpoint increased by ~$25M to $14.725B

revenueepsguidancefree cash flowoperating margins

Risk Factors

  • Organic revenue growth of 3.1% is modest and below total reported growth of 5.8%
  • Total debt increased to $6.33B from $5.58B at year-end due to debt pre-funding
  • Accounts receivable increased $187.9M, pressuring working capital
  • Adverse weather impacted organic volume growth (1.1% vs 1.8% price/mix)

Market Snapshot

Exchange
NYSE
Sector
Services-Medical Laboratories
Analyst Consensus
79% bullish (29 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000920148-26-000135
Document: lh-20260430.htm0000920148-26-000135
Document: 0000920148-26-000135-index-headers.html0000920148-26-000135
Document: 0000920148-26-000135-index.html0000920148-26-000135
Document: 0000920148-26-000135.txt0000920148-26-000135
8-K Data (Synthetic)0000920148-26-000135

Track record

29 reports on LH

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +14.54% at T+20 after the Oct 15, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $372.32 Now $372.46 +0.04% settles Nov 19
  2. Nov 10, 20266d ago 144 Neutral 2/10 Entry $372.23 Now $372.46 +0.06% settles Nov 18
  3. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $363.30 to $372.32 Now $372.46 +2.52% ▲ +2.48% −0.81% vs SPY
  4. Nov 4, 202612d ago 144 Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
  6. Nov 3, 202613d ago 144 Neutral 2/10 Entry $353.92 to $370.88 Now $372.46 +5.24% ▲ +4.79% +5.38% vs SPY
  7. Oct 30, 202617d ago 144 Neutral 2/10 Entry $361.39 to $366.57 Now $372.46 +3.06% ▲ +1.43% +4.14% vs SPY
  8. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $360.25 to $367.79 Now $372.46 +3.39% ▲ +2.09% +2.81% vs SPY
  9. Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $329.90 to $361.39 Now $372.46 +12.90% ▲ +9.55% +10.81% vs SPY
  10. Oct 21, 202626d ago 8-K Neutral 2/10 Entry $323.75 to $331.17 Now $372.46 +15.05% ▲ +2.29% +2.74% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens Wed (10h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026